Allogene療法 ALLO 深 滬
等待開盤 05-19 09:30:00 美东时间
1.94
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 1.94
- 總市值 6.70亿
- 52周最高 4.46
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.9842
- 委 比 0.00%
- 總股本 3.45亿
- 歷史最高 55.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.8621
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多电话会总结 ｜ Allogene(ALLO)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Allogene业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **2026年第一季度财务表现：** - **研发费用**：3200万美元，其中包含270万美元非现金股权激励费用 - **管理费用**：1410万美元，其中包含560万美元非现金股权激励费用 - **净亏损**：4260万美元，合每股亏损0.18美元 - **非现金股权激励总费用**：830万美元 - **现金及现金等价物**：截至3月31日为2.669亿美元 - **融资收入**：4月份通过公开发行获得约2.004亿美元总收入 ## 2. 财务指标变化 **费用指导上
05-14 12:10
Allogene Therapeutics Q1 2026 Earnings Call Transcript
Allogene Therapeutics (NASDAQ:ALLO) released first-quarter financial results an...
05-14 06:12
Allogene Highlights ALPHA3 Data and Extended Cash Runway
An announcement from Allogene Therapeutics ( ($ALLO) ) is now available. On May...
05-14 05:04
Allogene Therapeutics Q1 EPS $(0.18) Beats $(0.19) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 35.71 percent increase over losses of $(0.28) per share
05-14 04:02
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Initial clinical data for AlloNK in refractory rheumatoid arthritis (RA) shows 71% ACR50 response at six months, with no relapses or new immunomodulatory agents needed. The treatment demonstrated good tolerability, supporting outpatient administration in community settings without cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Over 70 autoimmune patients have been treated across 40 clinical site...
05-08 10:30
Allogene Therapeutics Receive South Korea, Australia Clearance To Expand Its Pivotal Phase 2 ALPHA3 Trial Of Cemacabtagene Ansegedleucel To Treat Patients With Large B-Cell Lymphoma
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that regulatory
04-21 20:31
Allogene Therapeutics to present allogeneic CAR-T data at AACR annual meeting
Allogene Therapeutics to present allogeneic CAR-T data at AACR annual meeting Allogene Therapeutics will present at AACR Annual Meeting in San Diego, April 17-22, 2026. Preclinical BCMA/CD70 dual CAR T poster session scheduled for April 20, 9:00 a.m.-12:00 p.m. PT. CEO David Chang will speak in majo
04-20 20:36
Allogene presents preclinical BCMA/CD70 dual CAR-T data for multiple myeloma at AACR
Allogene presents preclinical BCMA/CD70 dual CAR-T data for multiple myeloma at AACR Allogene Therapeutics disclosed new preclinical work on an allogeneic dual-target CAR-T program targeting BCMA and CD70 for high-risk multiple myeloma. Data will be presented at AACR 2026 on April 20 in a poster ses
04-20 20:31
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
